Although many patients respond to PD-1 therapies, the PD-1 blockade is not enough to activate immune cells in many patients. Further stimulation (“hitting the gas”) through OX40 and CD137 agonism, has been shown to have incremental therapeutic benefit.
FS120 provides a coordinated, robust immune response with a favorable preclinical safety profile and is expected to provide a wide therapeutic window in cancer patients. Its triple immune activation mechanism of action has the potential to improve standard of care treatment outcomes.
Our Approach for Improving PD-1 and Chemotherapy Responses with FS120:
- First-in-class OX40/CD137 mAb² dual agonist bispecific antibody
- Dual activation of cytotoxic CD8+ and CD4+ T helper cells and reprogramming of T regs, leading to an anti-tumor immune response in preclinical models
- Conditionally active and Fc gamma receptors (FcγR) null for improved safety
- Opportunity to transform current treatment paradigms in combination with standard of care
- Phase I monotherapy trial ongoing to support combination with PD-1
